<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00072839</url>
  </required_header>
  <id_info>
    <org_study_id>CL0600-008-01</org_study_id>
    <nct_id>NCT00072839</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease</brief_title>
  <official_title>A Pilot Study of the Safety and Efficacy of ALX-0600 in Subjects With Moderately Active Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether an investigational compound, ALX-0600, is
      safe and effective in treating Crohn's Disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is twelve weeks in duration and there are eight weeks of once-daily injections into
      your abdomen or thigh. There are a total of six visits.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy variable is the percentage of subjects who respond to treatment, defined as the percentage of subjects who are in remission (CDAI less than 150) or have a 100-point or greater reduction from baseline in CDAI score at dosing Week 8.</measure>
    <time_frame>8 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The various secondary efficacy variables are based on the CDAI, Inflammatory Bowel Disease Questionnaire (IBDQ), plasma citrulline and laboratory inflammatory markers.</measure>
    <time_frame>8 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo solution injected subcutaneously daily into either thigh or abdomen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>teduglutide 0.05</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>teduglutide 0.05 mg/kg/d injected subcutaneously daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>teduglutide 0.1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.1 mg/kg/d teduglutide injected subcutaneously into thigh or abdomen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>teduglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.2 mg/kg/d teduglutide injected subcutaneously into thigh or abdomen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALX-0600</intervention_name>
    <description>teduglutide</description>
    <arm_group_label>teduglutide</arm_group_label>
    <other_name>GATTEX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo solution injected subcutaneously</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>teduglutide 0.05</intervention_name>
    <description>0.05 mg/jg/d subcutaneous daily injection into thigh or abdomen</description>
    <arm_group_label>teduglutide</arm_group_label>
    <other_name>GATTEX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>teduglutide 0.2 mg</intervention_name>
    <description>0.2 mg/kg/d subcutaneously injected into thigh or abdomen</description>
    <arm_group_label>teduglutide</arm_group_label>
    <other_name>GATTEX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teduglutide 0.05 dose</intervention_name>
    <description>0.05 mg/kg/d subcutaneous daily injection into thigh or abdomen</description>
    <arm_group_label>teduglutide 0.05</arm_group_label>
    <other_name>GATTEX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>teduglutide 0.1 mg dose</intervention_name>
    <description>0.1 mg/kg/d daily subcutaneous injection into thigh or abdomen</description>
    <arm_group_label>teduglutide 0.1</arm_group_label>
    <other_name>GATTEX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Men and women, 18 years of age and older

          2. Signed and dated informed consent to participate before any study-related procedures
             are performed

          3. Diagnosis of Crohn's disease for at least 6 months that has been documented and
             confirmed

          4. A Crohn's Disease Activity Index (CDAI) score of 220 to 450 inclusive

          5. Female subjects who are not surgically sterile or postmenopausal must use medically
             acceptable methods of birth control during and for 30 days after the treatment period.

          6. HCT 30% or greater

          7. WBC 3.5 x 109/L or greater

          8. Platelets 100 x 109/L or greater

          9. Adequate renal function defined as: serum creatinine and BUN 1.5 x ULN or less

         10. Adequate hepatic function defined as: ALT/SPGT, AST/SGOT 2.0 x ULN or less; total
             bilirubin 1.25 x ULN or less, alkaline phosphatase 1.5 x ULN or less

         11. Female subjects of childbearing potential must have negative urine pregnancy test
             results prior to randomization

         12. A stool sample must be taken at screening and analyzed by a local laboratory for
             enteric pathogens, pathogenic ova and parasites, and Clostridium difficile toxin, and
             reported negative prior to randomization.

         13. C-reactive protein value must be 1.0 mg/dL or more, unless there are obvious
             manifestations of currently active Crohn's disease such as positive observations on
             endoscopy, other positive indications by laboratory test results, or the subject has
             had a previous intestinal resection for Crohn's disease.

        Exclusion Criteria

          1. Nutritionally compromised subjects requiring enteral or parenteral therapy to maintain
             weight

          2. Body weight less than 40 kg or more than 100 kg

          3. Bowel obstruction or any condition that may predispose to its development, intestinal
             perforation, or significant gastrointestinal hemorrhage

          4. Current ileostomy or colostomy or extensive external fistulization (more than 3
             external fistulae which are expressible with gentle compression)

          5. Expected to require surgical therapy for Crohn's disease or Crohn's disease related
             complications within 12 weeks of screening. If an abscess is present, it should be
             drained at least 3 weeks before pre-screening

          6. History of ulcerative colitis within 6 months of screening visit

          7. Cushing's syndrome

          8. Known HIV infection, or symptoms or signs of HIV infection

          9. Acute systemic infection and/or intestinal infection requiring antibiotic therapy at
             time of screening or baseline

         10. Evidence of chronic hepatitis B or C viral infection

         11. Decompensated liver disease

         12. Clinically significant ECG abnormalities

         13. History of angina or cardiac arrhythmia requiring drug or device intervention or
             clinically significant congestive heart failure or other clinically significant
             cardiac disease

         14. History of myocardial infarction within 12 months of screening

         15. History of thromboembolic disease (e.g., phlebitis, pulmonary embolus) or known
             congenitally or acquired prothrombotic disorder (e.g., protein C deficiency)

         16. History of cancer (other than resected cutaneous basal or squamous cell carcinoma or
             in situ cervical cancer) or clinically significant lymphoproliferative disease with
             fewer than 5 years documented disease-free state

         17. Known substance abuse in the previous 2 years

         18. Nursing mothers or pregnant women

         19. Use of native GLP-2, growth hormone, or growth factors within 3 months of signing
             informed consent

         20. Use of any of the prior or concomitant medications described in section 5.4, except as
             specified

         21. Known hypersensitivity to any of the active or inactive constituents of ALX-0600
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Jacobs, MD</last_name>
    <role>Study Director</role>
    <affiliation>NPS Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advanced Clinical Therapeutics</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Gastroenterology</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rx Trials</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Management of Boca Raton</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Venture Research</name>
      <address>
        <city>N. Miami Beach</city>
        <state>Florida</state>
        <zip>33162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visions Clinical Research - Sarasota</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Trials</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Health System</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342-1764</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60619</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Clinical Research Associates</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asher Kornbluth, MD, PC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital-Allegheny Ctr for Digestive Diseases</name>
      <address>
        <city>Pittsburg</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital/Baylor University</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGuire DVAMC</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dean Foundation Research Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odyssey Research</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8T 5G4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Sciences Center</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Life Screening Centres</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S 2A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Buchman AL, Katz S, Fang JC, Bernstein CN, Abou-Assi SG; Teduglutide Study Group. Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease. Inflamm Bowel Dis. 2010 Jun;16(6):962-73. doi: 10.1002/ibd.21117.</citation>
    <PMID>19821509</PMID>
  </reference>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2003</study_first_submitted>
  <study_first_submitted_qc>November 12, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2003</study_first_posted>
  <last_update_submitted>November 10, 2015</last_update_submitted>
  <last_update_submitted_qc>November 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

